PARP inhibitors in ovarian cancer

Elisena Franzese, Sara Centonze, Anna Diana, Francesca Carlino, Luigi Pio Guerrera, Marilena Di Napoli, Ferdinando De Vita, Sandro Pignata, Fortunato Ciardiello, Michele Orditura

Research output: Contribution to journalReview article

Abstract

Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways, particularly homologous recombination (HR) deficiency. In this review, we provide an updated overview of the available results of recent clinical trials on the three Food and Drug Administrationand European Medicines Agency approved PARPis in ovarian cancer: olaparib, niraparib, and rucaparib. Furthermore, we anticipate the future perspective of combination regimens with antiangiogenic, immunocheckpoint inhibitors, and other biological agents as strategies to overcome resistance mechanisms, potentiate the therapeutic efficacy, and expand their clinical use in non-HR deficient tumors.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalCancer Treatment Reviews
Volume73
DOIs
Publication statusPublished - 2019

    Fingerprint

Cite this

Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Di Napoli, M., De Vita, F., Pignata, S., Ciardiello, F., & Orditura, M. (2019). PARP inhibitors in ovarian cancer. Cancer Treatment Reviews, 73, 1-9. https://doi.org/10.1016/j.ctrv.2018.12.002